Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BW-201 RSV Vaccine Phase III Trial in Adults Aged 60 Years and Older
ChiCTR2600130214Phase 3Not yet recruiting
- Sponsor
- Hebei Provincial Center for Disease Control and Prevention
- Start
- Aug 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary infection, acute respiratory illness (ARI) and respiratory syncytial virus lower respiratory tract infection comparing BW-201 vaccine arm with Placebo arm (2 arms). Primary endpoints: Incidence of RSV-associated LRTD (first occurrence) during first RSV season (S1) and Incidence of sLRTD related to RSV subtype A and subtype B during first RSV season (S1). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
BW-201
03
Conditions
pulmonary infectionacute respiratory illness (ARI)respiratory syncytial virus lower respiratory tract infection
Beyond the preview
Go deeper on ChiCTR2600130214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130214.